Trodelvy gets EU nod for first-line triple-neg breast cancer
A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...
Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.
Changing Faces: Board appointments, June and July 2026
Board appointments June/July brought together veterans from across the pharmaceutical industry, venture capital, healthcare technology, and academia
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe
Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.